Financial Data and Key Metrics Changes - In 2024, Xiaomi Group achieved total revenue of JPY365.9 billion, a year-on-year increase of 35% [8] - Adjusted net profit reached JPY27.2 billion, reflecting a year-on-year increase of 41% [8] - The comprehensive gross profit margin for the year was 20.9%, showing stable performance [28] - In Q4 2024, revenue exceeded RMB100 billion for the first time, reaching RMB109 billion, with a year-on-year growth of 48.8% [27] Business Line Data and Key Metrics Changes - Mobile phone revenue for 2024 was RMB191.8 billion, accounting for 52.4% of total revenue, with a year-on-year growth of 21.8% [29] - IoT and consumer products revenue exceeded RMB100 billion for the first time, increasing by 30% year-on-year to RMB104.1 billion [34] - Internet services revenue reached RMB34.1 billion, a new historical high with a year-on-year increase of 13.33% [37] Market Data and Key Metrics Changes - Xiaomi's global smartphone shipments were 168.5 million units, a year-on-year increase of 15.7%, maintaining a market share of 13.8% [30] - In the Chinese market, the proportion of high-end smartphones reached 23.3%, a year-on-year increase of 3 percentage points [32] - The wearable wristband products ranked second globally with a market share of 15.2% [11] Company Strategy and Development Direction - The company is focusing on a "Human, Car, and Home" strategy, aiming for high-end development across all product categories [13][24] - Xiaomi plans to expand its retail network to 20,000 stores by the end of 2025, including 500 overseas stores [19] - The company aims to increase R&D investment to JPY30 billion in 2025, emphasizing technological innovation [14] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of technological innovation and the potential for growth in overseas markets, which are expected to be twice the size of the domestic market [53] - The company anticipates a stable operating environment with some price volatility in components, but expects overall growth in the high-end product segment [75] - Management expressed confidence in achieving higher profitability in the automobile business in the coming years, despite current losses [82] Other Important Information - Xiaomi's R&D expenditure reached RMB24.1 billion in 2024, an increase of 25.9% compared to the previous year [41] - The company was recognized as a Chinese ESG model enterprise, reflecting its commitment to social responsibility [44] Q&A Session Summary Question: Regarding the EV business and production capacity - Management confirmed that they are improving production capacity and have set a target of delivering 350,000 units [52] Question: Plans for overseas expansion and resource allocation - Management indicated that overseas markets present significant growth potential, with ongoing expansion of Xiaomi Home stores in various countries [55] Question: AI adoption and investment - Management acknowledged that true AI adoption is still a few years away, with significant investment planned for AI technologies [61] Question: Impact of national subsidies on growth - Management clarified that national subsidies had minimal impact on Q4 growth, particularly for mobile phones [72] Question: Future profitability of the automobile business - Management stated that while the automobile business is currently in a heavy investment phase, they expect improvements in gross margins and profitability in the future [82] Question: Growth in the Internet business - Management attributed the growth in the Internet business to an expanding user base and increased advertising revenue [84] Question: Retail network expansion speed and future forecast - Management confirmed plans to expand the retail network significantly, aiming for 20,000 stores by 2025 [92] Question: Opportunities in large home appliances - Management expressed optimism about growth potential in large home appliances, emphasizing their competitive edge in smart technology [102]

Xiaomi Corporation 2024 Fourth Quarter and Annual Results Disclaimer By attending the meeting where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by representatives of Xiaomi Corporation (the "Company", and together with its subsidiaries, the "Group") for use in presentations by the Group and does not constitute a recommendation regarding the securities of the Group. No part of t ...

Fourth Quarter and Full Year 2024 Earnings Call March 17, 2025 Cautionary Statement Regarding Forward-looking Statements Pursuant to Safe Harbor Provisions of The Private Securities Litigation Reform Act of 1995 Cautionary Statement Regarding Forward-Looking Statements This presentation includes "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995. Forward–looking statements include statements concerning Kodak's plans, objectives, goals, strategies, ...

Financial Data and Key Metrics Changes - Sangamo Therapeutics reduced non-GAAP operating expenses by nearly half year-over-year since 2023 [9] - The company raised over $100 million in funding through non-dilutive license fees, milestone payments, and equity financing in 2024 [9] Business Line Data and Key Metrics Changes - The company advanced its neurology therapies, securing its first-ever neurology IND for idiopathic small fiber neuropathy [7] - The Fabry gene therapy study continues to generate best-in-class data, with pivotal data readout expected in mid-2025 [9][22] Market Data and Key Metrics Changes - Interest in the Fabry program has been strong, with ongoing business development negotiations for a commercial partner [11] - The company is actively engaged in advanced contract negotiations for a third STAC-BBB license agreement [13] Company Strategy and Development Direction - Sangamo's number one priority is addressing financing needs to ensure the company is well-capitalized for future success [11] - The company aims to secure a partnership for the Fabry program by the second quarter of 2025 [12] - The regulatory pathway for accelerated approval in Fabry disease could reduce the time to potential approval by approximately three years [8][29] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the progress made in transitioning to a clinical-stage neurology company [28] - The company is focused on raising additional capital to support its programs and is in late-stage negotiations for a third STAC-BBB license agreement [30] Other Important Information - The company plans to begin patient enrollment and dosing for ST-503 in mid-2025, with preliminary proof of efficacy data expected in the fourth quarter of 2026 [19] - The FDA has provided a clear regulatory pathway to accelerate approval for ST-920, with full 52-week data expected in the first half of 2025 [25] Q&A Session Summary Question: Is the company still waiting on any data for the Fabry program? - Management confirmed they are in late-phase discussions with several partners and are looking forward to positive data from the ongoing studies [34] Question: Have potential partners seen any data beyond the WORLDSymposium data? - Management indicated that while partners have seen broader data, they have not seen later efficacy data beyond what was presented [45] Question: What is the status of the STAC-BBB deal? - Management hopes to finalize the deal by the end of the quarter and indicated that the partner is a logical blue-chip choice [55] Question: How is the company managing operating expenses going forward? - The company has reduced operating expenses significantly and plans to maintain the same level of expenses as last year while advancing its neurology pipeline [58] Question: What are the patient enrollment criteria for the Nav1.7% study? - Management stated that the criteria will be published on clinical trial registries, emphasizing the importance of a clear result for the one-time treatment [73]

Financial Data and Key Metrics Changes - In Q4 2024, consolidated revenue was $94.8 million, down from $104.8 million in Q3 and $119.2 million in the prior year period [28] - The net loss for Q4 was $215.8 million, compared to net income of $1.6 million in Q3 and a net loss of $10.2 million in the prior year period, primarily due to a non-cash impairment charge of $215 million related to the Sunrise Coal subsidiary [28][29] - Operating cash flow increased to $38.9 million in Q4, compared to cash used of $12.9 million in Q3 and $20.1 million in the prior year period [29] - Adjusted EBITDA for Q4 was $6.2 million, down from $9.6 million in Q3 but up from $2.1 million in the prior year period [30] Business Line Data and Key Metrics Changes - Electric sales in Q4 were $69.7 million, down from $71.7 million in Q3 and up from $37.1 million in the prior year period, while coal sales were $23.4 million, down from $31.7 million in Q3 and $91.7 million in the prior year period [27] - Hallador Power generated 1.16 million megawatt hours in Q4, up 5% from 1.1 million megawatt hours in Q3 [23] Market Data and Key Metrics Changes - The forward energy and capacity sales position increased to $685.7 million as of December 31, 2024, compared to $616.9 million at the end of Q3 [31] - Total liquidity at December 31, 2024, was $37.8 million, up from $34.9 million at September 30, 2024 [32] Company Strategy and Development Direction - The company is transitioning from a coal producer to a vertically-integrated power producer, aligning with market trends favoring the IPP model [7][8] - A significant milestone was reached with a non-binding term sheet signed with a global data center developer, indicating a strategic partnership that could drive long-term value [8][9] - The company is actively evaluating additional strategic transactions to expand electric operations and enhance scale [20] Management's Comments on Operating Environment and Future Outlook - Management noted that the transition from dispatchable to non-dispatchable generation increases the value of Hallador Power due to its reliability [10] - There are expectations for favorable pricing trends in 2025 and beyond, particularly related to data center development in Indiana [12][15] - The company anticipates that energy price volatility could increase over the next decade, sustaining a premium in forward power prices [16][17] Other Important Information - The company invested $13.8 million in capital expenditures during Q4, with total CapEx for 2024 at $53.4 million [31] - The company reduced total bank debt to $44 million in Q4, down from $70 million at the end of Q3 [32] Q&A Session Summary Question: Regulatory and review process with the grid operator - Management highlighted multiple access requests from developers, indicating a favorable environment for potential sales [36][37] Question: Remaining items before reaching a definitive agreement - Management indicated that they are encouraged by the progress made and the financial commitments from counterparties [41][42] Question: Capital intensity of upgrades at Merom - Management confirmed that studies are underway to assess the feasibility of coal firing with natural gas by 2032 [44][45] Question: Acquisition of other power assets - Management stated that they are exploring opportunities across various states and evaluating them on a case-by-case basis [49][50] Question: Pricing expectations for deals - Management expects a premium to the forward curves due to increasing demand from data centers and hyperscalers [68] Question: Control over fuel supply for future assets - Management noted that while control over fuel supply is advantageous, it is not a strict requirement for future acquisitions [63][64]

Financial Data and Key Metrics Changes - Total operating expenses for full year 2024 were $66.6 million, down 17% year-over-year [24] - R&D expenses for the full year 2024 were $40.2 million, down from $47.6 million in 2023 [24] - GAAP net loss for full year was $63.2 million, equating to a net loss of $10.74 per share, compared to a GAAP net loss of $71.1 million or $14.60 per share for the full year 2023 [25] Business Line Data and Key Metrics Changes - General and administrative expenses totaled $21.9 million in the full year 2024, down from $26.9 million in 2023 [24] - Sales and marketing expenses were $4.5 million compared to $6.2 million in the prior year [24] Market Data and Key Metrics Changes - The company has expanded its partnerships with leading U.S. hospital systems, including LSU Health New Orleans, Temple Health, and University of Illinois Health [13][15] - The company is preparing for its first clinical use of the Version 1.0% system, which is expected to treat patients later in the year [21] Company Strategy and Development Direction - The company aims to transition into a clinical stage company in 2025, with a focus on robotic surgery innovations [8] - The Version 1.0% system is designed to deliver differentiated value to patients, surgeons, and hospitals, with a focus on minimally invasive outcomes [10][12] - The company is building a robust supply chain and manufacturing foundation to support its clinical trials and future growth [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed excitement about the successful completion of the Version 1.0% system integration and the potential impact on surgical procedures [9][28] - The company anticipates treating its first clinical patients by year-end 2025, with a de novo submission expected to be late in 2026 [21][26] Other Important Information - The company has faced some procurement challenges with key suppliers, but has managed to mitigate the impact on its timelines [20][36] - A new CFO, Sarah Romano, will join the company on April 1, bringing extensive financial leadership experience [22][23] Q&A Session Summary Question: Can you provide details on the supplier dynamic and its impact on clinical trial manufacturing? - Management acknowledged material procurement challenges with key suppliers that led to delays in component deliverables, but noted that they have resumed production [35][37] Question: When do you anticipate the clinical trial beginning? - Management indicated that the first patients will be treated later in the year, with plans to kick off pivotal trials shortly after [41][42] Question: Can you provide timing around the dossier submission? - The dossier submission is expected around the middle of the year, with the first patient timing dependent on approval [51] Question: What were the results of the cadaver lab tests? - The cadaver labs successfully performed ventral hernia repairs, and management expressed confidence in the system's performance [61] Question: Any updates on clinical trial design and patient expectations? - Management confirmed that trial design will be finalized after the first patients, allowing for flexibility in protocol adjustments [64]

March 17, 2025 Legal Information IMPORTANT ADDITIONAL INFORMATION " Fourth Quarter & Full Year 2024 Earnings In connection with the proposed acquisition of Akoya Biosciences, Inc. ("Akoya") by Quanterix (the "Merger"), Quanterix filed with the U.S. Securities and Exchange Commission (the "SEC") a registration statement on Form S-4, dated February 13, 2025 (the "Registration Statement"), which contains a preliminary joint proxy statement of Quanterix and Akoya and a preliminary prospectus of Quanterix (the " ...

F O U R T H Q U A R T E R 2 0 2 4 FINANCIAL RESULTS © 2024 ENERGY VAULT, ALL RIGHTS RESERVED | Confidential FOUO (For Official Use Only) - PROPRIETARY INFORMATION OF ENERGY VAULT, INC 1 Disclaimer Forward-Looking Statements This presentation includes forward-looking statements that reflect the Company's current views with respect to, among other things, the Company's operations and financial performance. Forward-looking statements include information concerning possible or assumed future results of operatio ...

Financial Data and Key Metrics Changes - The company achieved 19% year-over-year growth in same-store adjusted community NOI and 27% growth in adjusted EBITDA for 2024 [8] - Pro forma NOI grew 9.6% in Q4 2024 compared to Q4 2023, with a pro forma NOI margin increase of 90 basis points [23][25] - Annual revenues increased by 7.5% due to a 180 basis points occupancy gain and nearly 6% RevPOR increase [25] Business Line Data and Key Metrics Changes - The company integrated 20 owned and 3 managed communities, resulting in a nearly 30% increase in total units [9] - The weighted average occupancy for newly acquired communities was 76% with an NOI margin of 21.7% [12] Market Data and Key Metrics Changes - Lead volume in Q4 2024 increased by 15% year-over-year, with tour volume up 11% in the same-store owned portfolio [18] - The company experienced a decline in weighted average occupancy to 86.6%, down 40 basis points from Q3 2024 [27] Company Strategy and Development Direction - The company aims for same-store NOI growth in the high end of its peer group for 2025, leveraging stabilized operations from recent acquisitions [11] - The focus is on capitalizing on demographic trends and supply-demand imbalances in senior living, with a strategy to pursue underperforming or mispriced assets [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2025, anticipating strong pricing and occupancy recovery, particularly in newly acquired communities [50][52] - The company is focused on controlling labor expenses and has not seen significant shifts in the labor market due to immigration changes [54] Other Important Information - The company executed six transactions totaling over $250 million in 2024, enhancing its acquisition capabilities and operational integrations [10] - Employee turnover decreased nearly 10% in 2024, indicating improved employee experience and retention [15] Q&A Session Summary Question: What is the current pricing trend compared to last year? - Management indicated that pricing is expected to remain strong in 2025, similar to gains seen in 2024, with continued occupancy levels supporting this [50] Question: What are the expectations regarding labor costs? - Management noted that labor expenses are being diligently managed, with no major shifts anticipated due to immigration changes, allowing for margin growth [54]

Financial Data and Key Metrics Changes - The company reported fourth-quarter revenue of $1.84 billion, an increase of 6% year-over-year, driven mainly by new program wins and on-contract growth [18] - Full-year fiscal year 2025 revenue reached $7.48 billion, representing 3.1% organic growth, which is at the high end of the guidance provided at the start of the year [19] - Fourth-quarter adjusted EBITDA was $177 million, resulting in a margin of 9.6%, while full-year adjusted EBITDA was $710 million with a margin of 9.5% [19][20] - Adjusted diluted earnings per share for the fourth quarter was $2.57 and $9.13 for the full year, benefiting from strong operating performance and a lower effective tax rate [19] Business Line Data and Key Metrics Changes - Revenue from the commercial operating sector increased from less than $1 million in fiscal year 2022 to approximately $45 million in fiscal year 2025, with a goal of reaching approximately $100 million by fiscal year 2028 [12] - The company delivered net bookings of $1.3 billion in the fourth quarter and $6.6 billion for fiscal year 2025, resulting in a book-to-bill ratio of 0.9% [15] Market Data and Key Metrics Changes - The company submitted bids totaling $28 billion in fiscal year 2025, exceeding the initial plan of $22 billion, with a backlog of submitted bids increasing to just over $20 billion at year-end [16] - The company expects to drive its book-to-bill ratio to the target of 1.2% by the first half of FY 2026, contingent on ongoing uncertainties facing customers [17] Company Strategy and Development Direction - The company is focusing on transitioning from cost-plus contracts to fixed-price contracts, which is expected to improve margins while maintaining revenue levels [46][50] - The strategy emphasizes mission-critical programs and the infusion of cutting-edge technology, aligning with government efficiency initiatives [9][56] - The company is assessing its cost-plus portfolio to determine how much work could transition to fixed-type contracting over time [14] Management's Comments on Operating Environment and Future Outlook - Management noted that the financial impact from recent executive orders and program cancellations has been nominal, but they remain prepared for potential changes in the operating environment [8] - The company anticipates a headwind of approximately $200 million related to low-margin Air Force CloudOne compute and store revenue, which they chose to no-bid [24] - Management expressed confidence in achieving free cash flow targets of $11 per share in fiscal year 2026 and $12 in fiscal year 2027 [20][26] Other Important Information - The company plans to repurchase between $350 million to $400 million in FY 2026 and 2027 while maintaining capacity for capability-focused M&A or additional share repurchases [26] - Several members of the executive leadership team have indicated an intent to make discretionary purchases of company shares to align interests with shareholders [28] Q&A Session Summary Question: Impact of the $1.8 billion recompete on future book-to-bill - Management indicated that the win would bring them close to a trailing twelve-month book-to-bill ratio of 1.0% [32] Question: Details on the incremental $6 billion in submitted bids - The increase is attributed to a combination of standardized business development functions and a balanced pipeline of new business and recompete opportunities [35] Question: Nature of budget dollars in the bid pipeline - Management believes the current pipeline is competitive and can be funded, with a focus on mission-critical areas [41] Question: Transition from cost-plus to firm fixed price contracts - Management sees potential for higher margins with fixed-price contracts but does not expect a significant revenue decline [48] Question: Risks and opportunities related to DOD budget cuts - Management emphasized the importance of focusing on mission-critical programs to mitigate risks associated with budget reallocations [56] Question: Impact of federal workforce layoffs on business - Management has not seen significant impacts but is prepared to support customers as personnel changes occur [66] Question: Backlog and organic growth expectations - A high percentage of the expected organic growth is already in backlog, with a focus on contract growth rather than relying heavily on new business [75] Question: Confidence in guidance despite uncertainty - Management expressed confidence based on past performance and ongoing efforts to drive organic growth [90] Question: Strategy regarding civil versus defense work - The company has not shifted its strategy and continues to focus on mission-critical areas in both civil and defense sectors [104]